A Hefty Price for Biosite

Beckman Coulter's $30-per-share premium for the maker of a heart disease test puzzles many. The deal may mean more consolidation lies ahead

Analysts anticipate further consolidation in the medical-devices sector after Beckman Coulter (BEC) said it would acquire cardiac diagnostic company Biosite (BSTE). The structure of the lumbering industry—where several major outfits dominate a long list of scrappier startups—has observers speculating that there will be more deals in the near future.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.